Umbilical cord blood transplantation

Area of Science:

• Hematology
• Transplantation Medicine
• Stem Cell Biology

Background:

• Umbilical cord blood (CB) has become a primary source for hematopoietic stem cell transplantation (HSCT) since 1998.
• Advantages include ease of procurement, donor safety, low infection risk, immediate availability, and HLA tolerance.
• Transplanted cell dose is critical for engraftment, limiting CB use in adult patients.

Purpose of the Study:

• To review the current status and future directions of umbilical cord blood transplantation (CBT).
• To highlight strategies aimed at improving engraftment and reducing mortality in CBT.
• To emphasize the growing acceptance of CB as an alternative HSCT source for adult recipients.

Main Methods:

• Review of existing literature and recent international studies on CBT.
• Analysis of strategies to enhance CBT efficacy, including reduced-intensity conditioning, double-unit CBT, ex vivo expansion, and MSC co-transplantation.
• Evaluation of the role of CB banking and processing advancements.

Main Results:

• Recent large-scale studies confirm CB as a viable alternative HSCT source for adult patients lacking matched donors.
• Ongoing research focuses on overcoming cell dose limitations and improving engraftment.
• Advancements in CB banking and processing are expected to increase its clinical application.

Conclusions:

• Umbilical cord blood transplantation is a well-established and increasingly utilized method for HSCT.
• Innovative strategies are expanding the therapeutic potential of CBT, particularly for adult populations.
• Continued research and development in CB banking will further enhance its role in treating various diseases.